Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names. The post Biotech Stocks Dive As Top 2% Names Take Hardest Hit appeared first on Investor's Business Daily.
CryptoAlerta — análise de criptomoedas e mercado em tempo real